Allogene Therapeutics (NASDAQ:ALLO) Posts Earnings Results, Beats Expectations By $0.06 EPS

Allogene Therapeutics (NASDAQ:ALLO) released its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06, Zacks reports.

Allogene Therapeutics Stock Performance

Shares of NASDAQ ALLO opened at $1.94 on Friday. Allogene Therapeutics has a 52-week low of $1.32 and a 52-week high of $4.89. The firm has a 50 day moving average price of $1.94 and a two-hundred day moving average price of $2.32. The stock has a market cap of $406.76 million, a P/E ratio of -1.24 and a beta of 1.02.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ALLO shares. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Friday. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research report on Friday. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.40.

Insider Transactions at Allogene Therapeutics

In other news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the sale, the insider now directly owns 250,713 shares in the company, valued at $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Zachary Roberts sold 27,199 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the sale, the executive vice president now owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 52,710 shares of company stock worth $92,125 over the last three months. 24.30% of the stock is owned by company insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).